All content for Biotalk is the property of Biotalk and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, explores the evolving biotech landscapes in Japan and China, highlighting key trends and developments shaping the region as featured in our 2024 Year-In-Review Report: Global Trends in Biopharma Transactions Report. Geoff leverages extensive conversations with strategics and investors worldwide to provide insights into global biotech deal-making. Key topics include:
Japan’s Recovery in 2024: A rebound in licensing activity reached $2.1B in Q4, driven by preclinical and small molecule deals. Venture financing grew 20%, with Series C and D rounds leading the charge.
China’s Strategic Transactions: Licensing deal value surged to $47B, driven by out-licensing, regulatory improvements, and NewCo formations. US investors are highly valued, with reverse mergers and IPOs becoming popular strategies for accessing US capital markets.
Key Themes: Japan’s focus on in-licensing signals interest in earlier-stage innovation, while China’s “fallen angel” assets provide US companies with cost-effective opportunities.
Looking ahead to 2025, Geoff discusses how stabilization in Japan and China’s growing innovation will shape global biotech, despite regulatory and geopolitical challenges.
Subscribe or follow Biotalk on Apple Podcasts | Spotify.
